Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02070991 · ClinicalTrials.gov registry record · Phase 2
Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction
A Phase 2 study, sponsored by Actelion.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT02070991 is a Phase 2 study that has completed, run by Actelion. The registered enrollment target is 63 participants.
The verdict
NCT02070991, a Phase 2 study, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of subjects with combined pre- and post-capillary pulmonary hypertension (CpcPH) due to left ventricular dysfunction.
Interventions
- DRUG Placebo
- DRUG Macitentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2014-07-01 |
| Est. Completion | 2015-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02070991
The ClinicalTrials.gov registry entry for NCT02070991 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02070991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02070991 about?
NCT02070991 is a clinical study titled "Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction". Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of subjects with combined pre- and post-capillary pulmonary hypertension (CpcPH) due to left ventricular dysfunction.
What is the current status of trial NCT02070991?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2014-07-01. Estimated completion is 2015-11-01.
What interventions are being tested in trial NCT02070991?
The interventions under investigation include: Placebo (DRUG), Macitentan (DRUG).
Who is sponsoring clinical trial NCT02070991?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.